Mide kanserinde CYFRA 21-1, CEA, CA 19-9 ve CA 72-4 düzeylerinin karşılaştırılması
Yükleniyor...
Tarih
2013
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Dicle Üniversitesi Tıp Fakültesi
Erişim Hakkı
Attribution-NonCommercial 3.0 United States
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Özet
Amaç: Mide kanseri dördüncü en sık görülen kanser olup, dünyada kanser ölümlerinin ikinci en sık nedenidir. Bu çalışmada mide kanserinin tanı ve takibinde tümör markırları olan CYFRA 21-1, CA 19-9, CEA ve CA 72-4’ün rollerinin araştırılması amaçlandı. Yöntemler: Çalışmamıza mide kanseri tanısı almış 30 hasta ve 30 sağlıklı birey alındı. Mide kanserli hasta grubunun TNM evrelendirme sistemine göre 16’sı Evre II, 14’ü Evre III idi. CEA, CA 19-9, CA 72-4 ve CYFRA 21-1 düzeyleri, elektrochemiluminescence immunasay (ECLIA) metod ile Cobas e 601 cihazında çalışıldı. Bulgular: Mide kanserli hasta grubunun CA 72-4, CA 19- 9, CEA ve CYFRA 21-1 düzeyleri sağlıklı kontrol grubuna göre istatistiksel olarak anlamlı yüksek bulundu (p<0.01). Mide kanserli hastalarda Evre III hasta grubunun CA 19- 9, CEA ve CYFRA 21-1 düzeyleri Evre II hasta grubuna göre istatistiksel olarak anlamlı yüksek bulundu (p<0.01). Tümör markırların kesim değerleri (cut-off), sensitivitesi ve spesifitesi sırayla; CEA için 4.15 ng/mL, %46 ve %96;
CA 19-9 için 24.50 U/mL, %17 ve %96; CA 72-4 için 2.46 U/mL, %53 ve %96 ve CYFRA 21-1 için 3.36 ng/mL, %46 ve %100 bulundu. Sonuç: Çalışmamızda mide kanserli hastaların takibinde CYFRA
Objective: Gastric cancer is the fourth most common malignancy, and the second most common cause of cancer mortality worldwide. The aim of this study was to investigate the role of biomarkers CYFRA 21-1, CA 19-9, CEA, CA72.4 at diagnosis and throughout the follow-up in patients with gastric cancer. Methods: 30 patients with gastric cancer diagnosed and 31 healthy people as a control group were included in this study. According to the TNM staging system, there were 16 patients with stage II and 14 patients with stage III in the group of patients with gastric cancer. CEA, CA 19-9, CA 72-4 and CYFRA 21-1 levels were studied by elektrochemiluminescence immunasay (ECLIA) method in the Cobas e 601 instrument. Results: Statistically the level of CA 72-4, CA 19-9, CEA and CYFRA 21-1 gastric cancer groups was found significant high accaording to healthy control group (p<0.01). Statistically compared with II stage patient group, the level of CA 19-9, CEA and CYFRA 21-1 of III stage patient group was found significant high (p<0.01). The diagnostic cut-off, sensitivity and specificity for CEA were 4.15 ng/ mL, 46 % and 96%, respectively; for CA 19-9 were 24.50 U/mL, 17 % and 96 %; for CA 72-4 were 2.46 U/mL, 53 % and 96% and for CYFRA 21-1 were 3.36 ng/mL, 46% and 100%. Conclusion: Our study demonstrates that the association of biomarkers CYFRA 21-1, CEA, and CA72.4 provides a valuable contribution in the follow-up of gastric cancer patients.
Objective: Gastric cancer is the fourth most common malignancy, and the second most common cause of cancer mortality worldwide. The aim of this study was to investigate the role of biomarkers CYFRA 21-1, CA 19-9, CEA, CA72.4 at diagnosis and throughout the follow-up in patients with gastric cancer. Methods: 30 patients with gastric cancer diagnosed and 31 healthy people as a control group were included in this study. According to the TNM staging system, there were 16 patients with stage II and 14 patients with stage III in the group of patients with gastric cancer. CEA, CA 19-9, CA 72-4 and CYFRA 21-1 levels were studied by elektrochemiluminescence immunasay (ECLIA) method in the Cobas e 601 instrument. Results: Statistically the level of CA 72-4, CA 19-9, CEA and CYFRA 21-1 gastric cancer groups was found significant high accaording to healthy control group (p<0.01). Statistically compared with II stage patient group, the level of CA 19-9, CEA and CYFRA 21-1 of III stage patient group was found significant high (p<0.01). The diagnostic cut-off, sensitivity and specificity for CEA were 4.15 ng/ mL, 46 % and 96%, respectively; for CA 19-9 were 24.50 U/mL, 17 % and 96 %; for CA 72-4 were 2.46 U/mL, 53 % and 96% and for CYFRA 21-1 were 3.36 ng/mL, 46% and 100%. Conclusion: Our study demonstrates that the association of biomarkers CYFRA 21-1, CEA, and CA72.4 provides a valuable contribution in the follow-up of gastric cancer patients.
Açıklama
Anahtar Kelimeler
Mide kanseri, Tümör belirteçleri, CYFRA 21-1, Gastric cancer, Tumor markers
Kaynak
Dicle Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
40
Sayı
2
Künye
Çakırca, G., Polat, C., İnal, A., Küçüköner, M., Mete, N., ve Işık, F.B. (2013). Mide kanserinde CYFRA 21-1, CEA, CA 19-9 ve CA 72-4 düzeylerinin karşılaştırılması. Dicle Tıp Dergisi, 40(2), 227-230.
